InVision Precision Cardiac Amyloid vs Reveal LINQ
AI Verdict
Choose InVision Precision Cardiac Amyloid if…
Choose InVision Precision Cardiac Amyloid if your cardiology practice needs an AI-powered solution to enhance the detection of cardiac amyloidosis from existing echocardiogram studies. This tool is ideal for clinicians assessing patients with heart failure symptoms who require precise, evidence-based analysis of wall thickness and earlier identification of both AL and ATTR cardiac amyloidosis.
View InVision Precision Cardiac Amyloid →Choose Reveal LINQ if…
Choose Medtronic Reveal LINQ if you need a long-term, continuous cardiac monitoring solution for patients experiencing infrequent or unexplained cardiac events like syncope or cryptogenic stroke. This implantable device provides up to three years of ECG recording with AI-powered algorithms to accurately detect arrhythmias, offering a comprehensive diagnostic approach when intermittent events are suspected.
View Reveal LINQ →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | InVision Precision Cardiac Amyloid | Reveal LINQ |
|---|---|---|
| Deployment | Cloud or on-premise | The Reveal LINQ ICM is an implantable device placed just beneath the skin in the upper left side of the chest through a small incision. The system includes a MyCareLink™ Monitor, a bedside unit that collects data from the ICM and sends it to the doctor. The Reveal LINQ Mobile Manager app, used by healthcare professionals, is downloaded to an iPad or Android tablet and paired via Bluetooth to a Medtronic patient connector, which communicates with the ICMs. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
InVision Precision Cardiac AmyloidTool A, as a software-only solution, integrates seamlessly into existing echocardiography workflows, requiring no invasive procedures for the patient. This generally leads to easier adoption and a less burdensome experience for both patients and clinicians compared to an implantable device like Tool B.
Clinical Value
TieBoth tools offer significant and distinct clinical value. Tool A provides crucial early detection for a severe, often underdiagnosed disease (cardiac amyloidosis) with strong scientific backing, including peer-reviewed publication in JAMA Cardiology. Tool B offers unparalleled long-term, continuous monitoring for various arrhythmias for up to three years, which is vital for managing conditions like cryptogenic stroke and significantly reduces false positives.
Pricing & Value
InVision Precision Cardiac AmyloidTool A offers transparent, publicly available starting pricing ($49/mo), which allows healthcare providers to more easily assess initial costs and budget. Tool B's pricing is not disclosed, making it difficult to evaluate its value proposition without direct vendor engagement.
Enterprise Readiness
InVision Precision Cardiac AmyloidTool A's nature as a Software as a Medical Device (SaMD) that integrates into existing echocardiography lab workflows suggests a simpler and more streamlined enterprise deployment. While Tool B is from a large enterprise, its deployment involves managing physical implantable devices, bedside monitors, and mobile apps, which adds layers of logistical complexity for healthcare systems.
Innovation
Reveal LINQTool B demonstrates superior innovation through its miniaturization as the world's smallest insertable cardiac monitor, offering an impressive three years of continuous ECG monitoring. Its AccuRhythmu2122 AI algorithms specifically address the critical challenge of reducing false alerts in long-term monitoring, which is a significant advancement in the field.
Support & Docs
Reveal LINQMedtronic, as a large and established medical device manufacturer, is expected to provide comprehensive support, training, and documentation for its implantable devices, including resources for both clinicians and patients. While InVision Medical Technology offers direct contact for deployment inquiries, specific details about its ongoing customer support infrastructure and publicly available documentation are not readily apparent.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | InVision Precision Cardiac Amyloid | Reveal LINQ |
|---|---|---|
| Name | InVision Precision Cardiac Amyloid | Reveal LINQ |
| Company | InVision Medical Technology Corporation | Medtronic |
| Primary Use Case/Detection | AI-powered software for echocardiography to detect cardiac amyloidosis | Implantable cardiac monitor to detect and diagnose cardiac arrhythmias, including atrial fibrillation, cryptogenic stroke, and unexplained syncope |
| AI Algorithm Focus | AI-powered detection of cardiac amyloidosis; Evaluation of transthoracic echocardiogram studies; Precise assessment of wall thickness | AccuRhythmu2122 AI algorithms for reduced false alerts (AF and pause) |
| Categories | Cardiology AI | Cardiology AI, Wearables & Remote Monitoring (RPM) |
| Specialties | Cardiology, Radiology | Cardiology, Neurology |
Videos
Demos, reviews, and walkthroughs featuring InVision Precision Cardiac Amyloid and Reveal LINQ.